Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 308 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: lipitor Clear all

Conditions: Type 1 Diabetes
Interventions: Evolocumab Cartridge, Atorvastatin Calcium Tablets, Ezetimibe Tablets, 18F-FDG, Angiocatheter 20IV, J-Wire, GlycoCheck Glycocalyx Measurement Software; Drug · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 89 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: New York, New York

Conditions: Arrhythmia
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and stable statin therapy, Stable statin therapy; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 13
States / cities: Santa Ana, California • Chicago, Illinois • Iowa City, Iowa + 10 more

Conditions: Lynch Syndrome
Interventions: Atorvastatin 20mg, Atorvastatin 20mg AND Aspirin 325 mg; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Systemic Lupus Erythematosus
Interventions: atorvastatin; Drug
Lead sponsor: The Center for Rheumatic Disease, Allergy, & Immunology; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Hypercholesterolemia
Interventions: Atorvastatin, Atorvastatin pediatric appropriate formulation; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and atorvastatin, Atorvastatin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 78
States / cities: Birmingham, Alabama • Northport, Alabama • Sierra Vista, Arizona + 75 more

Conditions: Nephropathy
Interventions: placebo, atorvastatin; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 100 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma

Conditions: Dyslipidemia
Interventions: PRC-4016, Placebo, Statins; Drug
Lead sponsor: Pronova BioPharma; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 29
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Beverly Hills, California + 24 more

Conditions: Hypercholesterolemia
Interventions: CAT-2054, Placebo, Atorvastatin; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 34
States / cities: Muscle Shoals, Alabama • Huntington Park, California • Lomita, California + 28 more

Conditions: Hypercholesterolemia
Interventions: Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 2,341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 115
States / cities: Huntsville, Alabama • Gilbert, Arizona • Sierra Vista, Arizona + 90 more

Conditions: Atherosclerosis, Cardiovascular Diseases, Hypertension, Renovascular, Renal Artery Obstruction
Interventions: Atacand/HCT, Caduet, GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting); Drug · Procedure
Lead sponsor: Baim Institute for Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 947 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Healthy
Interventions: Atorvastatin, ASC42; Drug
Lead sponsor: Gannex Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Dyslipidemia
Interventions: Slo-Niacin, atorvastatin; Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Alzheimer's Disease
Interventions: MRI, MR Spectroscopy, MR Perfusion; Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 45 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atrial Fibrillation, Arrhythmia, Inflammation, Endothelial Dysfunction
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Effect of Atorvastatin on the Pharmacokinetics of Lomitapide
Interventions: lomitapide, Atorvastatin; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus
Interventions: Rosuvastatin, Atorvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 29
States / cities: Avondale, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 26 more

Conditions: Hyperlipidemia, Dyslipidemia, Hypercholesterolemia
Interventions: torcetrapib/atorvastatin, simvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 49
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 46 more

Conditions: Dyslipidemia
Interventions: LCP-AtorFen; Drug
Lead sponsor: Asahi Kasei Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hyperlipidemia
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 48
States / cities: Huntsville, Alabama • Union Grove, Alabama • Fresno, California + 40 more

Conditions: Diastolic Heart Failure
Interventions: Atorvastatin, placebo; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pharmacokinetics
Interventions: ABT-335, Atorvastatin, Ezetimibe; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Neurocognitive Dysfunction
Interventions: atorvastatin; Drug
Lead sponsor: Duke University; Other
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study

Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia

Atorvastatin ± Aspirin in Lynch Syndrome Syndrome

Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors

Bioequivalence Study Of Pediatric Appropriate Formulation

Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia

Efficacy of Statins In Prevention of CIN

Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia

A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions

Drug Interaction Study of ASC42 With Atorvastatin

SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia

Statins in Cerebral Blood Flow and Neuronal Activity--A Pilot Study

The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation

Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.

Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.

12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia

Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.

Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients

A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe

Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery